$GILD News Earnings boost Micron, drag on Contai
Post# of 44846
Posted On: 01/14/2014 3:25:42 PM
$GILD News
Earnings boost Micron, drag on Container Store 4:25 p.m. Jan. 8, 2014 - Sue Chang
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
3 top trades for 2014 6:01 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - Russ Britt
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Sue Chang
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Standard Review for Gilead's Oncology Candidate - Analyst Blog 11:50 a.m. Today - Zacks.com
The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians 10:20 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Is the Downturn Serious? 8:09 p.m. Jan. 13, 2014 - TheStreet.com
Biotech Stocks Back On Top, Led By Biogen, Alexion 5:07 p.m. Jan. 13, 2014 - Investors Business Daily
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:01 p.m. Jan. 13, 2014 - TheStreet.com
Gilead Sciences Becomes #45 Most Shorted S&P 500 Component, Replacing Intuit 3:34 p.m. Jan. 13, 2014 - TheStreet.com
Growth Portfolio Playoffs Round 2: Gilead Vs. Wolverine World Wide 12:40 p.m. Jan. 13, 2014 - Seeking Alpha
J.P. Morgan Healthcare Confab Live Blog: Day One 10:19 a.m. Jan. 13, 2014 - TheStreet.com
FDA Accepts NDA for Gilead's Idelalisib for Treatment of Refractory Indolent Non-Hodgkin's Lymphoma 7:33 a.m. Jan. 13, 2014 - benzinga.com
3 Large-Cap Mutual Funds to Anchor Your Portfolio 6:57 a.m. Jan. 13, 2014 - InvestorPlace.com
Cramer's Lightning Round - I Can't Get My Arms Around The New Kodak (1/10/14) 6:29 a.m. Jan. 12, 2014 - Seeking Alpha
Cramer's Mad Money - 11 Earnings To Watch In The Week Ahead (1/10/14) 6:26 a.m. Jan. 12, 2014 - Seeking Alpha
Best Biotech Ideas for 2014 1:35 p.m. Jan. 11, 2014 - Barrons.com
Where to Find Yield 4:00 a.m. Jan. 11, 2014 - Barrons.com
Market Reaction Muted to Disappointing Jobs Data 6:15 p.m. Jan. 10, 2014 - TheStreet.com
If History Repeats, Biotech Traders Will Have Fun Next Week. Here's Why. 11:56 a.m. Jan. 10, 2014 - TheStreet.com
Stock Market News for January 10, 2014 - Corporate Summary 10:06 a.m. Jan. 10, 2014 - Zacks.com
Don't Underestimate Amgen: Part 1 7:45 a.m. Jan. 10, 2014 - Seeking Alpha
'Fast Money' Recap: Jumping Into Retail 5:00 a.m. Jan. 10, 2014 - TheStreet.com
Healthcare Picks By Drug Type In 2014 8:59 a.m. Jan. 9, 2014 - Seeking Alpha
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
Earnings boost Micron, drag on Container Store 4:25 p.m. Jan. 8, 2014 - Sue Chang
Buying the 2014 recovery 12:01 a.m. Jan. 7, 2014 - Jim Lowell
Goldman's biotech downgrade and the new consensus 11:53 a.m. Jan. 6, 2014 - MarketWatch.com
3 top trades for 2014 6:01 a.m. Dec. 30, 2013 - Jeff Reeves
Investors warm up to Gilead's test results; shares climb 5% by close 4:49 p.m. Dec. 18, 2013 - Russ Britt
Twitter hits record; Campbell, Starbucks head south 4:25 p.m. Dec. 10, 2013 - Sue Chang
Speculators should retain a flexible approach 1:41 p.m. Dec. 4, 2013 - The Trading Deck
Nasdaq’s climb reflects vast shifts in global economy 10:19 a.m. Nov. 27, 2013 - Dan Strumpf
Nasdaq makes first close above 4,000 in 13 years: stock market live blog recap 5:03 p.m. Nov. 26, 2013 - blogs.marketwatch.com
AbbVie shares up on Hepatitis C results, but gains may be muted 11:49 a.m. Nov. 18, 2013 - Russ Britt
Dan Loeb ups stake in FedEx, Google, trims Yahoo 5:41 p.m. Nov. 14, 2013 - Sital S. Patel
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
LinkedIn, Yelp decline; Baidu rallies after hours 5:14 p.m. Oct. 29, 2013 - Wallace Witkowski
Gilead profit up 17% as HIV drugs top sales growth 4:07 p.m. Oct. 29, 2013 - MarketWatch.com
Gilead shares rise 1% in late trading 3:59 p.m. Oct. 29, 2013 - Laura Mandaro
Earnings season focus shifts to revenue, capex 8:53 a.m. Oct. 27, 2013 - Wallace Witkowski
Healthcare stocks fall from first place in race for year's best-performing sector 2:32 p.m. Oct. 24, 2013 - blogs.marketwatch.com
In focus: Overbought conditions abound 7:21 p.m. Oct. 23, 2013 - Lawrence G. McMillan
Best Buy tops S&P 500; Netflix snaps losing streak 3:21 p.m. Oct. 10, 2013 - Sue Chang
Best Buy, Gilead Sciences lead S&P 500 gainers 3:05 p.m. Oct. 10, 2013 - Polya Lesova
Standard Review for Gilead's Oncology Candidate - Analyst Blog 11:50 a.m. Today - Zacks.com
The Short Story Of Intercept Pharmaceuticals (Part I): A Conference Call With Expert Physicians 10:20 a.m. Today - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Is the Downturn Serious? 8:09 p.m. Jan. 13, 2014 - TheStreet.com
Biotech Stocks Back On Top, Led By Biogen, Alexion 5:07 p.m. Jan. 13, 2014 - Investors Business Daily
Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard 5:01 p.m. Jan. 13, 2014 - TheStreet.com
Gilead Sciences Becomes #45 Most Shorted S&P 500 Component, Replacing Intuit 3:34 p.m. Jan. 13, 2014 - TheStreet.com
Growth Portfolio Playoffs Round 2: Gilead Vs. Wolverine World Wide 12:40 p.m. Jan. 13, 2014 - Seeking Alpha
J.P. Morgan Healthcare Confab Live Blog: Day One 10:19 a.m. Jan. 13, 2014 - TheStreet.com
FDA Accepts NDA for Gilead's Idelalisib for Treatment of Refractory Indolent Non-Hodgkin's Lymphoma 7:33 a.m. Jan. 13, 2014 - benzinga.com
3 Large-Cap Mutual Funds to Anchor Your Portfolio 6:57 a.m. Jan. 13, 2014 - InvestorPlace.com
Cramer's Lightning Round - I Can't Get My Arms Around The New Kodak (1/10/14) 6:29 a.m. Jan. 12, 2014 - Seeking Alpha
Cramer's Mad Money - 11 Earnings To Watch In The Week Ahead (1/10/14) 6:26 a.m. Jan. 12, 2014 - Seeking Alpha
Best Biotech Ideas for 2014 1:35 p.m. Jan. 11, 2014 - Barrons.com
Where to Find Yield 4:00 a.m. Jan. 11, 2014 - Barrons.com
Market Reaction Muted to Disappointing Jobs Data 6:15 p.m. Jan. 10, 2014 - TheStreet.com
If History Repeats, Biotech Traders Will Have Fun Next Week. Here's Why. 11:56 a.m. Jan. 10, 2014 - TheStreet.com
Stock Market News for January 10, 2014 - Corporate Summary 10:06 a.m. Jan. 10, 2014 - Zacks.com
Don't Underestimate Amgen: Part 1 7:45 a.m. Jan. 10, 2014 - Seeking Alpha
'Fast Money' Recap: Jumping Into Retail 5:00 a.m. Jan. 10, 2014 - TheStreet.com
Healthcare Picks By Drug Type In 2014 8:59 a.m. Jan. 9, 2014 - Seeking Alpha
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma 8:30 a.m. Jan. 13, 2014 - BusinessWire - BZX
Biotoscana agrees to acquire United Medical to expand commercial presence in Brazil and create a leading regional specialty pharmaceutical company in South America 1:15 a.m. Jan. 13, 2014 - BusinessWire - BZX
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13 5:00 p.m. Jan. 10, 2014 - BusinessWire - BZX
Retirement Announcements, Stock Price Movements, and Scheduled Conferences Presentations - Research Report on Gilead, Aegerion, Celldex, Alnylam, and Ironwood 8:00 a.m. Jan. 9, 2014 - PR Newswire
Stock Price Movements, Conference Presentation Schedules, and Expanded Sharing of Clinical Data - Research Report on Gilead, Express Scripts, Sanofi, Agilent, and Kythera Biopharma 8:00 a.m. Jan. 8, 2014 - PR Newswire
Galectin Therapeutics Receives Patent for Combination Treatment for Liver Fibrosis 12:17 p.m. Jan. 7, 2014 - ACCESSWIRE
Notable Buzzers: Apple Inc, Stereotaxis Inc, Tiger Oil and Energy Inc, Gilead Sciences Inc 11:00 a.m. Jan. 7, 2014 - ACCESSWIRE
Gilead Sciences' Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire 4:29 p.m. Jan. 6, 2014 - BusinessWire
Critical Alerts For Trina Solar, Gilead Sciences, Priceline, Akamai, and Anglogold Ashanti Released By InvestorsObserver 9:31 a.m. Jan. 2, 2014 - PR Newswire
Technical Briefing on Health Care Sector: Gilead Sciences, Halozyme Therapeutics, NPS Pharma, and InterMune 8:00 a.m. Dec. 26, 2013 - PR Newswire
Clinical Trial Results, Stock Movements, Grants & Donations, and Drug Resubmissions - Research Report on Gilead, WellPoint, Zoetis, Teleflex, and Orexigen 8:00 a.m. Dec. 23, 2013 - PR Newswire
Obesity Stock Plays Standing Out from the Crowd 10:04 a.m. Dec. 20, 2013 - ACCESSWIRE
Gilead Sciences Tops List of California's Most Honored Companies in Institutional Investor's All-America Executive Team Ranking 8:00 a.m. Dec. 19, 2013 - Marketwire
Gilead Announces SVR12 Rates From Three Phase 3 Studies Evaluating a Once-Daily Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Genotype 1 Hepatitis C Patients 8:30 a.m. Dec. 18, 2013 - BusinessWire
FDA Consents, Pending Acquisition Approvals, Program Deployments, and Stock Movements - Research Report on Gilead, Elan, Agilent, Alkermes and Hospira 8:00 a.m. Dec. 18, 2013 - PR Newswire
Critical Insider Analysis: MGM Resorts International, Groupon Inc, Gilead Sciences, Barrick Gold Corporation 9:30 a.m. Dec. 17, 2013 - ACCESSWIRE
FDA Approvals, Dividends, Promoting Diversity, Result Publications and Acquisitions - Research Report on Gilead, St. Jude Medical, Cigna, Pharmacyclics, and LifePoint 8:00 a.m. Dec. 17, 2013 - PR Newswire
Health Canada Issues Notice of Compliance for Sovaldi(TM) (Sofosbuvir) for the Treatment of Chronic Hepatitis C 8:30 a.m. Dec. 16, 2013 - BusinessWire
U.S. FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera(R) for Patients Switching from a Stable Regimen 4:30 p.m. Dec. 13, 2013 - BusinessWire
HealthStat Rx: Curing Hepatitis C (HCV) With Confidence 10:07 a.m. Dec. 12, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼